Impact of LDL-Apheresis on inflammation and microcirculation

Atherosclerosis Supplements

Volumn 10, Issue 5, 2009, Pages 56-58

  Koziolek, Michael J ^a   Mueller, Gerhard A ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

LDL cholesterol; LIPID apheresis; Lipoproteins

Indexed keywords

ADRENALIN; BIOLOGICAL MARKER; BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

APHERESIS; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; ENDOTHELIUM CELL; ERYTHROCYTE AGGREGATION; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; MICROCIRCULATION; PLASMA VISCOSITY; PLEIOTROPY; PRIORITY JOURNAL; STEM CELL; VASOCONSTRICTION; VASODILATATION;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; ENDOTHELIUM, VASCULAR; HEMODYNAMICS; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPROTEIN(A); LIPOPROTEINS, LDL; MICROCIRCULATION; TREATMENT OUTCOME;

EID: 72649103275     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(09)71812-4     Document Type: Article

References (28)

1. Apple F.S., Wu A., Mair J., Ravkilde J., Panteghini M., et al. Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin Chem 51 (2005) 810-824
2. Bohl S., Kassner U., Eckardt R., Utz W., Mueller-Nordhorn J., Busjahn A., Thomas H.P., Abdel-Aty H., Klingel R., Marcovina S., Dietz R., Steinhagen-Thiessen E., Schulz-Menger J., and Vogt A. Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging. Ther Apher Dial 13 (2009) 129-137
3. Bosch T., Wendler T., Jaeger B.R., and Samtleben W. Improvement of hemorheology by DALI apheresis: acute effects on plasma viscosity and erythrocyte aggregation in hypercholesterolemic patients. Ther Apher Dial 5 (2001) 372-376
4. Brunner R., Widder R.A., Walter P., Borberg H., and Oette K. Change in hemorrheological and biochemical parameters following membrane differential filtration. Int J Artif Organs 18 (1995) 794-798
5. Dihazi H., Koziolek M.J., Söllner T., Kahler E., Neuhoff R., Klingel R., Strutz F., and Mueller G.A. Proteomic adsorption during LDL-apheresis: Proteomic analysis. Nephro Dial Transplant 23 (2008) 2925-2935
6. Grundy S.M., Cleeman J.I., Merz N.B., Brewer H.B., Clark Jr. L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., and for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent trials for the national Cholesterol educations program adult treatment panel III guidelines. Circulation 110 (2004) 227-239
7. Kassenärztliche Bundesvereinigung: Mitteilungen: Zum Beschluss des Bundesausschusses der Ärzte und Krankenkassen vom 24. 3. 2003 zu den therapeutischen Apheresen. Deutsches Ärzteblatt 30 (2003) 2035-2036
8. Khuseyinova N., and Koenig W. Biomarkers of outcome from cardiovascular disease. Curr Opin Crit Care 12 (2006) 412-419
9. Kobayashi S., Moriya H., Maesato K., Okamoto K., and Ohtake T. LDL- apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J Clin Apher 20 (2005) 239-243
10. Kojima S. Low-density lipoprotein apheresis and changes in plasma components. Ther Apher 5 (2001) 232-238
11. Koziolek MJ, Hennig U, Zapf A, Bramlage C, Grupp C, Armstrong VW, Strutz F, Mueller GA: Retrospective analysis of long-term Lipidapheresis at a single centre. Ther Apher Dial, 2009, in press
12. Krieter D.H., Steinke J., Kerkhoff M., Fink E., Lemke H.D., Zingler C., Müller G.A., and Schuff-Werner P. Contact activation in low-density lipoprotein apheresis systems. Artif Organs 29 (2005) 47-52
13. Matschke K., Mrowietz C., Sternitzky R., Jung F., and Park J.W. Effect of LDL apheresis on oxygen tension in skeletal muscle in patients with cardiac allograft vasculopathy and severe lipid disorder. Clin Hemorheol Microcirc 30 (2004) 263-271
14. Mellwig K.P., van Buuren F., Schmidt H.K., Wielepp P., Burchert W., and Horstkotte D. Improved Coronary Vasodilatatory Capacity byH.E.L.P. Apheresis: Comparing Initial and Chronic Treatment. Ther Apher Dial 10 (2006) 510-517
15. Moriarty P.M., Gibson C.A., Kensey K.R., and Hogenauer W. Effect of low- density lipoprotein cholesterol apheresis on blood viscosity. Am J Cardiol 93 (2004) 1044-1046
16. Moriarty P.M., Gibson C.A., Shih J., and Matias M.S. C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158 (2001) 495-498
17. Nishimura S., Sekiguchi M., Kano T., Ishiwata S., Nagasaki F., Nishide T., Okimoto T., Kutsumi Y., Kuwabara Y., Takatsu F., Nishikawa H., Daida H., and Yamaguchi H. Effects of intensive lipid lowering by low- density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan low-density lipoprotein apheresis prospective study (L-CAPS). Atherosclerosis 144 (1999) 409-417
18. Otto C., Geiss H.C., Laubach E., and Schwandt P. Effects of direct adsorption of lipoproteins apheresis on lipoproteins, low-density lipoprotein subtypes, and hemorheology in hypercholesterolemic patients with coronary artery disease. Ther Apher 6 (2002) 130-135
19. Patschan D., Patschan S., Henze E., Koziolek M., and Müller G.A. Lipid apheresis rapidly increases peripheral endothelial progenitor cell proliferation. J Clin Apher 24 (2009) 180-185
20. Sakurai M, Muso E, Matushima H, Ono T, Sasayama S: Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome. Kidney Int Suppl., 1999, 71
21. Schettler V., Wieland E., Armstrong V.W., Kleinoeder T., Grunewald W., Müller G.A., and the Participants of the Göttingen Consensus Conferences. First Steps toward the establishment of a German low-density lipoproteinapheresis registry: recommendations for the indication and for the quality management. Ther Apher 6 (2002) 381-383
22. Stokes K.Y., Cooper D., Tailor A., and Granger D.N. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic Biol Med 33 (2002) 1026-1036
23. Thompson G.R. LDL Apheresis. Atherosclerosis 167 (2003) 1-13
24. Tsuchida H., Shigematsu H., Ishimaru S., Iwai T., Akaba N., and Umezu S. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS). Int Angiol 25 (2006) 287-292
25. Utsumi K., Kawabe M., Hirama A., Ueda K., Kamada Y., Arii K., Komaba Y., Katsura K., Iino Y., and Katayama Y. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin Chim Acta 377 (2007) 198-200
26. Wang Y., Blessing F., Walli A.K., Uberfuhr P., Fraunberger P., and Seidel D. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins-reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 175 (2004) 145-150
27. Whayne Jr. T.F., Zielke J.C., Dickson L.G., and Winters J.L. State of the art treatment of the most difficult low density lipoprotein (LDL) cholesterol problems: LDL apheresis. J Ky Med Assoc 100 (2002) 535-538
28. Wieland E., Schettler V., and Armstrong V.W. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis 162 (2002) 187-191